Form 4: Oric Pharmaceuticals Director Angie You Boosts Stake with Significant Stock Purchases

Oric Pharmaceuticals Director Angie You has increased her beneficial ownership in the company through two recent stock purchases totaling 28,000 shares.

Summary

• Angie You, a Director at Oric Pharmaceuticals, Inc. (ORIC), acquired 26,597 shares of common stock on June 20, 2025, at a weighted average price of $9.3871 per share.
• An additional 1,403 shares of common stock were purchased on June 23, 2025, at a price of $9.43 per share.
• Following these transactions, Ms. You beneficially owns a total of 28,000 shares of Oric Pharmaceuticals common stock.
• The purchases were made directly by the reporting person.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant insider buying, indicating confidence from a company director in the company's valuation and future prospects.

Positives

• The stock purchases by a company director indicate strong insider confidence in Oric Pharmaceuticals' future prospects and valuation.
• Insider buying can often be viewed positively by the market, suggesting that those with the most intimate knowledge of the company believe its stock is undervalued or poised for growth.

Future Outlook

This Form 4 filing reports past transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is specific to an insider transaction at Oric Pharmaceuticals and does not provide broader industry trends or context. However, insider buying can be a signal of management's perception of the company's position within its industry.

Related Party Transactions

• Director Angie You purchased 26,597 shares of Oric Pharmaceuticals common stock at a weighted average price of $9.3871 on June 20, 2025.
• Director Angie You purchased an additional 1,403 shares of Oric Pharmaceuticals common stock at $9.43 on June 23, 2025.

Stakeholder Impact

• Shareholders may view the insider purchases as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees and other stakeholders might interpret the director's increased stake as a sign of stability and belief in the company's long-term strategy.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Insider Trading, Stock Purchase, SEC Form 4, Beneficial Ownership, Director, Equity Acquisition